<DOC>
	<DOCNO>NCT03054467</DOCNO>
	<brief_summary>The aim present study compare effect CCB CCB+ high dose statin therapy symptom , function , quality life assess validated angina-specific questionnaire ( Short-form Seattle Angina Questionnaire ( SAQ-7 ) ) , endothelial function measure FMD brachial artery , endothelial progenitor cell ( EPC ) coronary flow reserve ( CFR ) patient VSA .</brief_summary>
	<brief_title>Effect Amlodipine Versus Amlodipine Combined With Atorvastatin Coronary Vasospastic Angina</brief_title>
	<detailed_description>STUDY DESIGN Study protocol Study Start ( expect FSFV ( First subject first visit ) ) August 1 2016 Study Stop ( expect LSLV ( Last subject last visit ) ) February 29 2019 150 Patients confirm VSA 3 episode angina per week 2 week qualification period randomly assign receive either amlodipine therapy ( NORVASC 10 mg/day ) amlodipine/atorvastatin combination ( CADUET 10/20mg ) 6 month . The start dose drung either 5mg amlodipine 5/20mg CADUET . After 4 week , 5mg amlodipine well tolerate , dose titrate 10mg 10/20mg CADUET . All antianginal medication proscribe study period except long-acting nitrate sublingual nitroglycerin require . Long-acting nitrate permit study period take constant dosage 2 week study entry . Participants allow take sublingual NTG need episode chest pain . Study design . Patients VSA 1 angina episodes/week confirm ergonovine provocation test Acquisition write consent Randomization NORVASC 10 mg/day CADUET 10/20 mg Baseline SAQ , angina diary , FMD , EPC , CFR assessment perform . Medication start either 5mg NORVASC 5/20mg CADUET . After 4 week , 5mg amlodipine well tolerate , titrate 10mg 10/20mg CADUET . Routine visit schedule reservation ( 2 3 month interval ) After 6-months treatment , follow-up SAQ , angina diary , FMD , EPC , CFR assessment perform ( mandatory ) . After 12-months treatment , follow-up SAQ , angina diary , FMD , EPC , CFR assessment perform ( optional ) . Efficacy assessment . The primary efficacy variable change summary score SAQ-7 NORVASC 10mg/day CADUET 10/20mg , weekly average frequency self-reported angina episodes 6-months treatment phase . Difference Summary score SAQ 7 calculate baseline ( enrollment randomization ) 6-months treatment . The study staff clinical site review angina nitroglycerin use diary patient study visit . Assessment patient response short form SAQ baseline 6 month treatment . The Seattle Angina Questionnaire ( SAQ ) validate disease-specific instrument assess health status patient coronary artery disease . Although SAQ frequently use clinical trial registry , use routine clinical care limited length ( 19 question ) absence single summary score facilitates overall assessment patient ' health status . Recently , 7-item Physical Limitation , Angina Frequency , Quality Life domain shorten version SAQ ( SAQ 7 ) , well overall summary score develop validated patient stable coronary artery disease , undergo percutaneous coronary intervention , present acute myocardial infarction .</detailed_description>
	<mesh_term>Angina Pectoris , Variant</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Amlodipine , atorvastatin drug combination</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>The investigator include patient newly diagnose VSA within 3 month screen patient without CCB 1month screening . VSA patient 3 episode angina per week 2week qualification period include . In addition angina symptom , follow two criterion diagnose VSA need satisfied : ( 1 ) spontaneous ergonovine induce coronary artery spasm ( produce 90 % narrowing coronary lumen diameter angiography ) associate chest pain ischemic ST segment change ( transient ST elevation depression 0.1 mV , record least two contiguous lead 12lead ECG ) ; ( 2 ) normal insignificant ( diameter stenosis 50 % ) coronary artery disease intracoronary nitroglycerine injection . The investigator exclude patient fix stenosis correspond â‰¥50 % lumen diameter coronary artery history allergic reaction amlodipine atorvastatin . Other exclusion criterion : ( 1 ) myocardial infarction within 3 month screen ; ( 2 ) history life threaten event associate previous episode coronary artery spasm , ventricular tachycardia , ventricular fibrillation , syncopal episode ; ( 3 ) decompensated congestive heart failure ; ( 4 ) significant valvular heart disease ; ( 5 ) systolic blood pressure 90 mm Hg ; ( 6 ) baseline heart rate 100 beats/min ; ( 7 ) ECG abnormalities preclude interpretation ST change ; ( 8 ) coronary artery bypass surgery percutaneous coronary intervention within 3 month screen ; ( 9 ) woman childbearing potential refuse use contraception ; ( 10 ) active hepatic renal disease ; ( 11 ) major concomitant disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>